"
Team:UCLA/Safety
From 2014.igem.org
Anuvedverma (Talk | contribs) |
Anuvedverma (Talk | contribs) |
||
| (7 intermediate revisions not shown) | |||
| Line 2: | Line 2: | ||
<html> | <html> | ||
| + | <!-- TITLE BANNER--> | ||
| + | <div style="position:relative;margin:auto;background-color:#050708;width:100%;height:100px;"> | ||
| + | <center><img style="padding: 0px 0px 0px 0px;" src="https://static.igem.org/mediawiki/2014/a/ae/IGEM_UCLA_Logo.PNG"></center> | ||
| + | <br/> | ||
| + | </div> | ||
<!--CONTENT--> | <!--CONTENT--> | ||
| - | <div | + | <div class= "content_container" style="top:200px;"> |
| - | + | <div class= "page_content" id= "section1"> | |
| - | + | <div class= "content_subsection" id="safety"> | |
| - | + | <h1>Safety</h1> | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | <div class = "page_content" id= " section1"> | + | |
| - | + | ||
| - | <div class = "content_subsection"> | + | |
| - | + | ||
| - | <h1>Safety</h1> | + | |
<h2>Training</h2> | <h2>Training</h2> | ||
<p><b>Briefly describe the topics that you learned about in your safety training.</b></p> | <p><b>Briefly describe the topics that you learned about in your safety training.</b></p> | ||
| Line 67: | Line 40: | ||
<p>We did not utilize any design features to mitigate risks. Expressing our protein causes the chassis bacteria to be metabolically disadvantaged, and so it would likely not survive in the wild.</p> | <p>We did not utilize any design features to mitigate risks. Expressing our protein causes the chassis bacteria to be metabolically disadvantaged, and so it would likely not survive in the wild.</p> | ||
| + | <h2>Standard Operating Procedures</h2> | ||
| + | <p>While the biological materials that we were working with did not present any hazards, a few of our solvents and chemicals did. Lithium bromide and hexafluoroisopropanol (HFIP) are used to solubilize natural and lyophilized silk, respectively. They were critical to our project, but due to their hazardous nature, we had to familiarize ourselves with how to safely and properly use them. We drafted the following Safe Operating Procedures for training and for reference:</p> | ||
| + | <a href="https://static.igem.org/mediawiki/2014/e/ed/HFIP_SOP.pdf">HFIP SOP </a><br/> | ||
| + | <a href="https://static.igem.org/mediawiki/2014/1/1f/LiBr_SOP.pdf">Anhydrous Lithium Bromide SOP </a> | ||
| + | </div> | ||
| + | </div> | ||
</html> | </html> | ||
Latest revision as of 01:01, 18 October 2014
Safety
Training
Briefly describe the topics that you learned about in your safety training.
Our safety training covered hazardous material storage and usage, biohazard usage practices, protective personal equipment, engineering and human safety controls, and in-depth properties of select hazards, such as peroxides and flammable compounds. The laboratory safety training requirements at UCLA can be found here
In your country, what are the regulations that govern biosafety in research laboratories? Please give a link to these regulations, or briefly describe them if you cannot give a link.
In the USA, biosafety regulations are provided by the Center for Disease Control and Prevention (CDC) and the American Biological Safety Association (ABSA), and National Institute of Health (NIH)
Project Risks
Risks to the safety and health of team members, or other people working in the lab:
E. coli K12 strain does not pose a major safety risk to humans. Nephila clavipes silk, which is the expressed protein product in our project, does not pose a safety risk either. Nevertheless, skin contact and potential ingestion should be eliminated or minimized.
Risks to the safety and health of the general public, particularly if any biological materials escaped from your lab:
Spider silk does not pose any safety or health risk to the environment if released. E. coli may have unpredictable impacts on the local ecosystem if released, but this is unlikely.
What measures are you taking to reduce these risks?
We chose a very safe chassis organism to use, K12 E.coli. We are also wearing proper Personal Protective Equipment, such as lab coats, gloves, and safety glasses when handling biological materials. Additionally, any surfaces that have been potentially contaminated by bacterial species are thoroughly cleaned using ethanol and/or bleach.
Risks of Your Project in the Future
What new risks might arise from your project's growth? Also, what risks might arise if the knowledge you generate or the methods you develop became widely available?
No safety risks would arise from the availability of our product or the knowledge of how to generate our product. There may be some impact to materials industries if the generation of genetically altered recombinant silk became commercially viable. For example, the natural silk industry may suffer if recombinant silk with altered properties became cheap.
Does your project currently include any design features to reduce risks? Or, if you did all the future work to make your project grow into a popular product, would you plan to design any new features to minimize risks?
We did not utilize any design features to mitigate risks. Expressing our protein causes the chassis bacteria to be metabolically disadvantaged, and so it would likely not survive in the wild.
Standard Operating Procedures
While the biological materials that we were working with did not present any hazards, a few of our solvents and chemicals did. Lithium bromide and hexafluoroisopropanol (HFIP) are used to solubilize natural and lyophilized silk, respectively. They were critical to our project, but due to their hazardous nature, we had to familiarize ourselves with how to safely and properly use them. We drafted the following Safe Operating Procedures for training and for reference:
HFIP SOPAnhydrous Lithium Bromide SOP
